JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. Stock
Equities
688076
CNE1000051X5
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.03 CNY | +2.30% |
|
+2.43% | +24.65% |
| Sales 2024 * | 1.47B 203M 278M | Sales 2025 * | 2.02B 279M 382M | Capitalization | 11.94B 1.65B 2.26B |
|---|---|---|---|---|---|
| Net income 2024 * | 232M 32.05M 43.86M | Net income 2025 * | 329M 45.44M 62.2M | EV / Sales 2024 * | 8.13 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 5.92 x |
| P/E ratio 2024 * |
51.5
x | P/E ratio 2025 * |
36.1
x | Employees | 1,545 |
| Yield 2024 * |
0.54% | Yield 2025 * |
0.85% | Free-Float | 52.6% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.30% | ||
| 1 week | +2.43% | ||
| 1 month | +5.12% | ||
| 3 months | +34.36% | ||
| 6 months | +20.91% | ||
| Current year | +24.65% |
1 week
53.35
56.60
1 month
49.4056.60
Current year
35.6358.97
1 year
27.4958.97
3 years
18.0993.30
5 years
18.0993.30
10 years
18.0993.30
| Managers | Title | Age | Since |
|---|---|---|---|
Zi Quan Tong
CEO | Chief Executive Officer | 54 | 17-08-31 |
Wei Ding
DFI | Director of Finance/CFO | 41 | 23-02-05 |
Biao Liu
CHM | Chairman | 43 | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qiang Guo Xu
BRD | Director/Board Member | 60 | 19-05-19 |
Feng Qu
BRD | Director/Board Member | 49 | 19-05-19 |
De Yi Zhao
BRD | Director/Board Member | 61 | 09-04-02 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 56.03 | +2.30% | 2,884,849 |
| 24-04-29 | 54.77 | -0.54% | 2,815,650 |
| 24-04-26 | 55.07 | +0.68% | 2,476,239 |
| 24-04-25 | 54.7 | +1.22% | 2,640,518 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd a China-based company principally engaged in the independent research and development and customized research and development and production of peptide drugs and small molecule drugs. The Company's main business includes customized product business and independently selected product business. Its customized product business includes CDMO (Contract Development and Manufacturing Organization) business, technical service CRO (Contract Research Organization) and transfer business. Its independently selected product business focuses on small molecule chemical drugs and conducts drug research and development in the key treatment areas of diabetes, cardiovascular diseases, tumors and other diseases. The Company mainly operates its businesses in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
56.03
CNY
Average target price
62.24
CNY
Spread / Average Target
+11.09%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +24.65% | 1.65B | |
| +26.08% | 681B | |
| +21.85% | 556B | |
| -4.77% | 361B | |
| +16.97% | 325B | |
| +5.69% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.40% | 157B |
- Stock Market
- Equities
- 688076 Stock
